When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

What caused Eli Lilly's stock to fall this week ... Lilly's specific guidance related to its blockbuster GLP-1 drugs, Mounjaro and Zepbound. For the fourth quarter, Lilly calls for revenue ...